Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM +1.63%75 Days Sales Outstanding is 265.86 as of Mar. 2026, which is 139% above its 10-year median of 111.28. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 75/100 and a GF Value™ of BDT19.44 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 413 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 91.77% on this metric.
Orion Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was BDT4,332 Mil. Orion Pharma's Revenue for the
three
months ended in Mar. 2026 was BDT1,487 Mil.
Hence, Orion Pharma's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 265.86.
The historical rank and industry rank for Orion Pharma's Days Sales Outstanding or its related term are showing as below:
DHA:ORIONPHARM'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.75 Med: 111.28 Max: 422.55
Current: 422.55
During the past 11 years, Orion Pharma's highest Days Sales Outstanding was 422.55. The lowest was 74.75. And the median was 111.28.
DHA:ORIONPHARM's Days Sales Outstanding is ranked worse than 91.77% of 413
companies
in the Utilities - Independent Power Producers industry
Industry Median: 64.64
vs DHA:ORIONPHARM: 422.55
Orion Pharma's Days Sales Outstanding
declined
from Mar. 2025 (470.94) to Mar. 2026 (265.86).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Orion Pharma (DHA:ORIONPHARM) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Orion Pharma Days Sales Outstanding Related Terms
Orion Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Days Sales Outstanding Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Days Sales Outstanding vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 265.86 mean?
Orion Pharma (DHA:ORIONPHARM) has a Days Sales Outstanding of 265.86 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Orion Pharma and its competitors. This is 139% above median its historical median of 111.28. Over the past decade, Orion Pharma's Days Sales Outstanding has ranged from 74.75 to 422.55. According to the industry distribution chart, Orion Pharma ranks #379 out of 413 companies in the Utilities - Independent Power Producers industry, placing it in the top 91.8%.
Is Orion Pharma's Days Sales Outstanding too high?
Orion Pharma's current Days Sales Outstanding of 265.86 is 139% above median its 10-year median of 111.28. Over the past 10 years, this metric has ranged from a low of 74.75 to a high of 422.55. The Utilities - Independent Power Producers industry median Days Sales Outstanding is 64.64. Orion Pharma's value of 265.86 is 311.3% above this industry median. Based on the distribution chart, Orion Pharma ranks #379 out of 413 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Days Sales Outstanding compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #379 out of 413 companies for Days Sales Outstanding. This places Orion Pharma in the lower half of its industry. The industry median Days Sales Outstanding is 64.64. Orion Pharma's value of 265.86 is 311.3% above this benchmark. Historically, Orion Pharma's own Days Sales Outstanding has ranged from 74.75 to 422.55 over the past decade. While the company's 10-year median is 111.28 vs. the industry median of 64.64, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for an Utilities - Independent Power Producers company?
The median Days Sales Outstanding among Utilities - Independent Power Producers companies is 64.64, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Days Sales Outstanding of 265.86 is 311.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Days Sales Outstanding is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Days Sales Outstanding is 265.86, which is 139% above median its own 10-year median of 111.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT19.44, compared to a current price of BDT25.00 — trading 28.6% above its estimated fair value. The current Days Sales Outstanding is 265.86, which is 139% above median its 10-year median of 111.28 and 311.3% above the Utilities - Independent Power Producers industry median of 64.64. Orion Pharma's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Days Sales Outstanding is 265.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT25.00 is trading 28.6% above its estimated GF Value™ of BDT19.44.
GuruFocus considers Orion Pharma to be Modestly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Days Sales Outstanding: 265.86 (139% above median its 10-year median of 111.28)
GF Value™: BDT19.44 vs. price of BDT25.00 (28.6% above fair value)
Industry Position: 311.3% above the Utilities - Independent Power Producers median (#379 of 413)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
75GF Score
Get the complete analysis for DHA:ORIONPHARM
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
